First-in-person trial for its Clevegen cancer treatment underway
Two patients dosed showed increases in natural killer cells and T-Cells
Faron says results much better than expected
Indicates that Clevegen might be able to reactivate T-Cells in cancer sufferers
How is it doing
A phase III trial as a treatment for lung inflammation condition ARDS proved a major disappointment.
There was no benefit against the placebo, though Faron (LON:FARN) is working with drug regulators to work out why the results were poor and are confident Tramaukine can be of benefit to some patients.
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic cutaneous melanoma as well as hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.
Tumour cells are adept at creating a shield around themselves to evade detection by the immune system, therefore staving off destruction.
Clevegen has been designed to recognise cancer and break the cell’s protective shell.
The treatment is an anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.
Ultimately, if it is successful, this new breed of treatment will be used in combination with PD-1 inhibitors to tackle the killer disease.
What the boss says: Markku Jalkanen, CEO
Speaking about the first results of the first three people dosed in the Clevegen trial
“Previously we had believed it was impossible to reactive the T-Cells within the cancer patients so these results are quite incredible,” he said.
“By the summer of this year, we should have a lot of questions answered,
"With a partner, we want to expand the trial in onto other cancer areas as well and as a combination therapy as well as a mono-immunotherapy."
More results from MATINS trial over a longer period
Faron finds a partner from the many said to be watching MATINS trial data
Traumakine reboots as a treatment for a specific type of ARDS sufferer who has a special type of genetic mutation known as C/T.
If Clevegen proves to a way of re-awakening T-cells in metastatic tumours, the potential as an immunotherapy treatment is enormous
Traumakine is a smaller opportunity now but still substantial for Faron, which at 60.5p is with £19mln.
Before the Traumakine trial result, the shares almost reached 900p.